Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

276 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial.
Manders SH, Kievit W, Adang E, Brus HL, Moens HJ, Hartkamp A, Hendriks L, Brouwer E, Visser H, Vonkeman HE, Hendrikx J, Jansen TL, Westhovens R, van de Laar MA, van Riel PL. Manders SH, et al. Among authors: van riel pl, van de laar ma. Arthritis Res Ther. 2015 May 22;17(1):134. doi: 10.1186/s13075-015-0630-5. Arthritis Res Ther. 2015. PMID: 25997746 Free PMC article. Clinical Trial.
Sustained beneficial effects of a protocolized treat-to-target strategy in very early rheumatoid arthritis: three-year results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort.
Vermeer M, Kuper HH, Moens HJ, Drossaers-Bakker KW, van der Bijl AE, van Riel PL, van de Laar MA. Vermeer M, et al. Among authors: van der bijl ae, van riel pl, van de laar ma. Arthritis Care Res (Hoboken). 2013 Aug;65(8):1219-26. doi: 10.1002/acr.21984. Arthritis Care Res (Hoboken). 2013. PMID: 23436821 Free article. Clinical Trial.
Initial combination therapy versus step-up therapy in treatment to the target of remission in daily clinical practice in early rheumatoid arthritis patients: results from the DREAM registry.
Steunebrink LM, Versteeg GA, Vonkeman HE, Ten Klooster PM, Kuper HH, Zijlstra TR, van Riel PL, van de Laar MA. Steunebrink LM, et al. Among authors: van riel pl, van de laar ma. Arthritis Res Ther. 2016 Mar 8;18:60. doi: 10.1186/s13075-016-0962-9. Arthritis Res Ther. 2016. PMID: 26956382 Free PMC article.
Effectiveness of a third tumor necrosis factor-α-blocking agent compared with rituximab after failure of 2 TNF-blocking agents in rheumatoid arthritis.
Blom M, Kievit W, Donders AR, den Broeder AA, Straten VH, Kuper I, Visser H, Jansen TL, Brus HL, Branten AJ, van de Laar MA, van Riel PL. Blom M, et al. Among authors: van riel pl, van de laar ma. J Rheumatol. 2011 Nov;38(11):2355-61. doi: 10.3899/jrheum.101324. Epub 2011 Sep 1. J Rheumatol. 2011. PMID: 21885487
Comparative responsiveness of the EuroQol-5D and Short Form 6D to improvement in patients with rheumatoid arthritis treated with tumor necrosis factor blockers: results of the Dutch Rheumatoid Arthritis Monitoring registry.
Buitinga L, Braakman-Jansen LM, Taal E, Kievit W, Visser H, van Riel PL, van de Laar MA. Buitinga L, et al. Among authors: van riel pl, van de laar ma. Arthritis Care Res (Hoboken). 2012 Jun;64(6):826-32. doi: 10.1002/acr.21619. Epub 2012 Jan 19. Arthritis Care Res (Hoboken). 2012. PMID: 22262513 Free article.
Treating to the target of remission in early rheumatoid arthritis is cost-effective: results of the DREAM registry.
Vermeer M, Kievit W, Kuper HH, Braakman-Jansen LM, Bernelot Moens HJ, Zijlstra TR, den Broeder AA, van Riel PL, Fransen J, van de Laar MA. Vermeer M, et al. Among authors: van riel pl, van de laar ma. BMC Musculoskelet Disord. 2013 Dec 13;14:350. doi: 10.1186/1471-2474-14-350. BMC Musculoskelet Disord. 2013. PMID: 24330489 Free PMC article.
276 results